摘要
Clesrovimab 為一種新型單株抗體,作用機轉為標靶呼吸道融合病毒 (respiratory syncytial virus, RSV) 融合蛋白預融合構型之IV 位點,並於Fc (fragment crystallizable) 區段引入YTE (M252Y/S254T/T256E) 突變以延長半衰期,單次肌肉注射後可於整個RSV 流行季節維持有效保護濃度。
於健康嬰兒族群進行之臨床試驗顯示,clesrovimab 可顯著降低醫療照護相關 (medically attended, MA) 之RSV 下呼吸道感染 (lower respiratory tract infection, LRI) 發生風險60.4% (95% confidence interval [CI], 44.1–71.9; p < 0.001),RSV 相關住院風險下降84.2% (95% CI, 66.6–92.6; p < 0.001),LRI 相關住院風險下降90.9% (95% CI, 76.9–96.9; p < 0.001),嚴重MA RSV LRI 發生風險則下降91.7% (95% CI, 62.9–98.1; p < 0.001)。於高風險嬰兒族群試驗中,clesrovimab 之臨床效益與現行標準治療palivizumab 相當,兩組在RSV相關感染與住院風險方面無顯著差異,整體安全性良好。
Clesrovimab 為美國食品藥品管理局 (Food and Drug Administration, FDA) 核准用於嬰兒RSV 預防之長效單株抗體之一,提供除nirsevimab 外另一種結合位點不同之被動免疫策略。綜上所述,在台灣可依現行指引並結合近年流行資料,由藥師參與以實證為基礎的共享決策評估clesrovimab 的適用性。
ABSTRACT
Clesrovimab is a novel monoclonal antibody that targets site IV on the prefusion conformation of the fusion glycoprotein of respiratory syncytial virus (RSV). It incorporates YTE (M252Y/S254T/T256E) substitutions in the Fc (fragment crystallizable) region to extend serum half-life, allowing a single intramuscular injection to maintain protective concentrations throughout the RSV season.
In the clinical trial involving healthy infants, clesrovimab significantly reduced the risk of medically attended (MA) RSV-associated lower respiratory tract infection (LRI) by 60.4% (95% confidence interval [CI] 44.1–71.9; p < 0.001), RSV hospitalizations by 84.2% (95% CI, 66.6–92.6; p < 0.001), LRI-related hospitalizations by 90.9% (95% CI 76.9–96.9; p < 0.001), and severe MA RSV LRI by 91.7% (95% CI 62.9–98.1; p < 0.001). In a trial involving high-risk infants, clesrovimab demonstrated clinical efficacy comparable to the current standard therapy, palivizumab, with similar rates of RSVrelated infections and hospitalizations. Overall safety and tolerability were favorable.
Clesrovimab is one of the long-acting monoclonal antibodies approved by the U.S. Food and Drug Administration for RSV prevention in infants, offering an alternative passive immunization strategy with a distinct binding epitope from nirsevimab. In summary, in Taiwan, clinicians should evaluate the appropriateness of clesrovimab through evidence based shared decision making that references current guidance and recent epidemiologic data and includes pharmacist participation.
Submitted for publication: 2025.07.17; Accepted for publication: 2025.11.13